Bioporto A/S
CSE:BIOPOR

Watchlist Manager
Bioporto A/S Logo
Bioporto A/S
CSE:BIOPOR
Watchlist
Price: 1.402 DKK 0.29% Market Closed
Market Cap: 637.4m DKK

Net Margin
Bioporto A/S

-238.5%
Current
-215%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-238.5%
=
Net Income
-82.1m
/
Revenue
34.4m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
DK
Bioporto A/S
CSE:BIOPOR
602.4m DKK
-238%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
327.3B USD
7%
US
Amgen Inc
NASDAQ:AMGN
155.6B USD
17%
US
Gilead Sciences Inc
NASDAQ:GILD
135.1B USD
21%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.3B USD
-9%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
116.3B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
55.2B USD
32%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
40.4B USD
-11%

Bioporto A/S
Glance View

Market Cap
602.4m DKK
Industry
Biotechnology

Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.

BIOPOR Intrinsic Value
HIDDEN
Show
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-238.5%
=
Net Income
-82.1m
/
Revenue
34.4m
What is the Net Margin of Bioporto A/S?

Based on Bioporto A/S's most recent financial statements, the company has Net Margin of -238.5%.

Back to Top